Home/Pipeline/Platform Application in Lung Cancer

Platform Application in Lung Cancer

Lung Cancer

Pre-clinical/ResearchActive

Key Facts

Indication

Lung Cancer

Phase

Pre-clinical/Research

Status

Active

Company

Oxford Cancer Analytics

About Oxford Cancer Analytics

Oxford Cancer Analytics is a private, pre-revenue diagnostics company founded in 2016 and based in Oxford, UK. It is developing a proprietary platform that combines high-throughput proteomic analysis of blood samples with advanced machine learning to generate diagnostic and prognostic insights for lung diseases, starting with COPD. The company's mission is to transform fragmented and slow diagnostic pathways by providing scalable, biologically grounded tools that enable earlier intervention and more consistent clinical decision-making. Led by a team with expertise in diagnostics, AI, and clinical medicine, OXcan represents a convergence of proteomics and computational biology aimed at a significant global health burden.

View full company profile

Therapeutic Areas

Chronic Obstructive Pulmonary Disease (COPD)Lung Cancer

Other Lung Cancer Drugs

Drug	Company	Phase	Status
OncoStrong™	Lamark Biotech	Preclinical	Active
15dPMJ2	Claradele Pharmaceuticals	Research	Exploratory (Pathway Implied)
SUPLEXA	Alloplex Biotherapeutics	Phase 1	Completed
Oncology Digital Biomarkers	Imvaria	Development	Active
Aerosolized Platinum Nanoparticles	HylaPharm	Pre-clinical	Active
ENV105	Kairos Pharma	Phase 1	Active
AI for Lung Cancer	Invenio Imaging	Research	Active
Liposome Program	NanoTech Pharma	Preclinical/Phase 1/2	Active
Dendritic Cell Vaccine	MegaNano BioTech	Pre-clinical	Active
AI Biomarkers for Lung Cancer	BioAI Health	Unknown	Active
PRDM2 Target	ARIZ Precision Medicine	Preclinical	Active
ZEN-3694	Zenith Epigenetics	Proof-of-Concept	Active